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Abstract
Objective: Animal studies suggest that regulatory T (Treg) cells play a beneficial role in ventricular remodeling and our
previous data have demonstrated defects of Treg cells in patients with chronic heart failure (CHF). However, the mechanisms
behind Treg-cell defects remained unknown. We here sought to elucidate the mechanism of Treg-cell defects in CHF patients.
Methods and Results: We performed flow cytometry analysis and demonstrated reduced numbers of peripheral blood
CD4
+CD25
+FOXP3
+CD45RO
2CD45RA
+ naı ¨ve Treg (nTreg) cells and CD4
+CD25
+FOXP3
+CD45RO
+CD45RA
2 memory Treg
(mTreg) cells in CHF patients as compared with non-CHF controls. Moreover, the nTreg/mTreg ratio (p,0.01),
CD4
+CD25
+FOXP3
+CD45RO
2 CD45RA
+CD31
+ recent thymic emigrant Treg cell (RTE-Treg) frequency (p,0.01), and T-cell
receptor excision circle levels in Treg cells (p,0.01) were lower in CHF patients than in non-CHF controls. Combined annexin-
V and 7-AAD staining showed that peripheral Treg cells from CHF patients exhibited increased spontaneous apoptosis and
were more prone to interleukin (IL)-2 deprivation- and CD95 ligand-mediated apoptosis than those from non-CHF
individuals. Furthermore, analyses by both flow cytometry and real-time polymerase chain reaction showed that Treg-cell
frequency in the mediastinal lymph nodes or Foxp3 expression in hearts of CHF patients was no higher than that of the non-
CHF controls.
Conclusion: Our data suggested that the Treg-cell defects of CHF patients were likely caused by decreased thymic output of
nascent Treg cells and increased susceptibility to apoptosis in the periphery.
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Introduction
Chronic heart failure (CHF) is regarded as a state of chronic
inflammation with elevated T-cell activation and inflammatory
cytokine production in the circulatory system [1,2]. However, the
pathogenic mechanisms responsible for this abnormal immune
activation remain unknown. Treg cells represent a unique lineage
of T cells that play an essential role in the modulation of immune
responses and the control of potentially harmful immune
activations because of their immunoregulatory and immunosup-
pressive characteristics [3]. Among the several types of Treg cells
that have been defined, one particular subset that constitutively
expresses CD4, CD25 and the transcription factor Foxp3 has
received much attention. Alterations in CD4
+CD25
+Foxp3
+ Treg-
cell number or function is directly associated with the pathogenesis
of several common human diseases, including acute coronary
syndrome (ACS) [4,5], multiple sclerosis [6], type 1 diabetes [7],
and rheumatoid arthritis [8]. Adoptive transfer of purified Treg
cells suppresses immune injury and improves recovery in animal
disease models [9–12].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24272Adverse ventricular remodeling occurs upon acute and chronic
injury regardless of etiology, and it is related to poor prognosis of
patients with heart failure [13]. There is compelling evidence that
inflammatory mechanisms contribute to the process of adverse
ventricular remodeling [14]. In animal models of heart failure,
previous studies demonstrated that Treg cells could be a target of
heart failure therapeutics because CCR5-mediated Treg-cell
recruitment in the infarcted heart [15] and adoptively transferred
Treg cells [16] provided protection from adverse cardiac
remodeling by preventing expansion of inflammation and fibrosis
after adoptive transfer. In a previous publication, we found that
circulating Treg cells were reduced and their function was altered
in CHF patients, regardless of etiology, suggesting that the defects
in Treg cells are responsible for the aberrant chronic immune
activation in CHF patients [17]. It is believed that the
understanding of mechanisms underlying Treg-cell defects in
CHF patients is of great significance, especially with respect to
therapy through Treg-cell manipulation. In the present study, we
attempt to explore the mechanisms that might account for the
Treg-cell defects in CHF patients by studying Treg-cell production,
survival, and tissue reallocation in these patients.
Results
1. Reduced nTreg-, mTreg- and RTE-Treg-cell frequency in
CHF patients
To determine the number of total Treg cells and Treg subsets,
PBMCs were obtained from 52 CHF patients and 43 age-matched
non-CHF controls followed by 6-color flow cytometric analysis.
Basic clinical characteristics of the study population are summa-
rized in Table 1. Within the naı ¨ve CD4
+CD45RA
+CD45RO
2
(R1 in Figure 1A) or memory CD4
+CD45RA
2CD45RO
+ (R2 in
Figure 1A) T cells, a small subpopulation of cells with high
expression of both CD25 and Foxp3 could be readily detected.
mTreg cells were characterized as CD4
+CD25
+Foxp3
+ CD45RA
2
CD45 RO
+ cells (R3 in Figure 1B, upper panel) and nTreg cells
were characterized as CD4
+CD25
+Foxp3
+CD45RA
+CD45RO
2
cells (R4 in Figure 1B, lower panel). nTreg cells exhibited a lower
expression of CD25 as compared with mTreg cells (mean
fluorescent intensity, MFI: nTreg vs. mTreg: 24.165.4 vs.
54.668.7, p,0.01). RTE-Treg cells were identified as CD31 co-
expressing nTreg cells (Figure 1C). The proportion of Treg cells in
total CD4
+ T cells was significantly decreased in CHF patients
when compared with non-CHF subjects (Figure 1D). The
percentages of nTreg and mTreg cells within CD4
+ T cells were
also significantly lower in CHF patients than in age-matched non-
CHF subjects (non-CHF vs. CHF patients: nTreg: 1.1760.41% vs.
0.5960.31%, p,0.01; mTreg: 3.2760.92% vs. 2.0260.65%,
p,0.01; Figure 1D). CHF patients showed a significantly lower
nTreg/mTreg ratio (non-CHF vs. CHF patients: 36610% vs.
30612%, p,0.05; Figure 1E). Furthermore, we observed that
proportions of RTE-Treg cells in the total Treg-cell population in
CHF patients were significantly reduced when compared to age-
matched, non-CHF controls, suggesting that thymic production of
Treg cells was impaired in CHF patients (non-CHF vs. CHF:
4.976.34% vs. 3.0060.97%, p,0.01; Figure 1F). However, no
difference in total Treg,n T reg,m T reg, and RTE-Treg cells between
IHF or NIHF patients was observed (Figure 1D–F). Similar results
were obtained when we compared the absolute numbers of total
Treg,n T reg,m T reg, and RTE-Treg cells between CHF patients and
non-CHF controls (Table 2).
Consistent with our previous report [17], we observed that total
Treg number was negatively correlated with NT-proBNP in CHF
patients. Furthermore, the present study also found that NT-
proBNP and nTreg or mTreg numbers were negatively correlated
(Table 3).
2. Decreased intracellular TREC levels in Treg cells from
CHF patients
TREC is a marker for nascent thymic T cells [18]. We studied
intracellular levels of TRECs in Treg cells isolated from 25 CHF
patients and 15 age-matched non-CHF subjects using quantitative
real-time PCR. Flow cytometry was used to determine the purity
of Treg cells after cell sorting (Figure 2A, left panel). The TREC
content in Treg cells was significantly lower in CHF than that in
non-CHF patients (non-CHF vs. CHF patients: 1.3860.49610
3/
10
6 cells vs. 0.6060.32610
3/10
6 cells, p,0.01; Figure 2A, right
panel). There was no significant difference in Treg-cell TREC
content between IHF and NIHF patients. Spearman’s correlation
test revealed a positive association between Treg-cell TREC level
and RTE-Treg cell proportion in both CHF patients and non-CHF
controls (r = 0.75, p,0.001; Figure 2B).
3. Increased spontaneous and IL-2 deprivation/Fas-
mediated apoptosis in Treg cells from CHF patients
Increased apoptosis and decreased survival could be a
mechanism of Treg-cell defects in CHF patients. Because of the
fixation and permeabilization procedures used for detecting Treg
cells using Foxp3 antibodies by FACS, we detected apoptotic Treg
cells with antibodies against CD127, a newly identified Treg
surface marker that correlates well with Foxp3 [19]. In both CHF
patients and non-CHF controls, CD4
+CD25
+Foxp3
+ Treg cells
were correlated with CD4
+CD25
+CD127
low/2 Treg cells (r=0.91,
p,0.001, Figure 3). When we gated the CD4
+CD25
+CD127
low/2
cells, we found that when this cell population was derived from
CHF patients, irrespective of the etiology, there was a significantly
higher percentage of apoptotic annexin V
+7-AAD
2 cells than
when derived from non-CHF controls (non-CHF vs. CHF patients:
8.7963.37% vs. 14.7864.08%, p,0.01; Figure 4A).
Enhanced apoptosis often correlates with altered expression of
apoptosis-associated genes. We compared the levels of anti-
apoptotic gene Bcl-2 and pro-apoptotic gene Bak expression
between CD4
+CD25
+CD127
low/2 Treg cells isolated from CHF
patients and non-CHF controls. Significantly lower Bcl-2 expres-
sion (p,0.01) and higher Bak expression (p,0.01) were observed
in Treg cells from CHF patients when compared with those from
non-CHF controls (Figure 4B).
IL-2 is essential for the development, function and homeostasis
of Treg cells [20]. However, human Treg cells do not produce this
cytokine and therefore are susceptible to IL-2 deprivation, which
leads to Treg-cell apoptosis [21]. Treg cells from CHF patients and
non-CHF controls might exhibit different susceptibilities to IL-2
deprivation. To test this hypothesis, we incubated Treg cells from
the different patient populations with anti-human IL-2 monoclo-
nal antibodies for 3 days. Treg cells from CHF patients were more
sensitive to IL-2 deprivation-induced apoptosis when compared
with Treg cells from non-CHF subjects (non-CHF vs. CHF:
22.3564.12% vs. 33.2665.89%, p,0.01; Figure 5A).
Treg-cell apoptosis could also be induced by the interactions
between death receptor CD95 with the CD95 ligand (CD95L)
[22]. Human Treg cells constitutively express these death receptors
and are thus highly sensitive to CD95-CD95L-mediated apoptosis
[23]. Increased apoptosis in Treg cells from CHF patients suggests
that Treg cells from these patients express high levels of CD95
and/or are more sensitive to CD95L. To test this hypothesis, we
compared the expression level of CD95 and sensitivity toward
CD95L-triggered apoptosis in Treg cells from CHF patients and
Mechanisms for Treg Defects in CHF Patients
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patients was significantly higher than on Treg cells from non-CHF
controls (non-CHF vs. CHF: 73.7868.12% vs. 84.3066.67%,
p,0.01; Figure 5B). CD95L induced apoptosis of Treg cells from
CHF patients in a dose- and time-dependent manner (Figure 5C).
CD95L initiated Treg-cell apoptosis in 3 hrs, but apoptosis reached
a peak after 12 hrs of induction. When incubated with 100 ng/ml
of CD95L for 12 hrs, Treg cells prepared from CHF patients
showed higher percentages of cells undergoing CD95L-induced
apoptosis than in non-CHF subjects (non-CHF vs. CHF patients:
19.4366.87% vs. 36.52612.03%, p,0.01; Figure 5D). These
observations could explain the increased Treg-cell apoptosis in
CHF patients (Figure 4A). Furthermore, we detected significantly
higher plasma levels of soluble CD95L in CHF patients than in
non-CHF controls (non-CHF vs. CHF patients: 77.2865.26% vs.
101.2265.06%, p,0.01; Figure 5E). Among the CHF subgroups
IHF and NIHF, we did not detect any differences in either IL-2
deprivation- or CD95-mediated Treg-cell apoptosis (Figure 5A/
5D). Plasma CD95L levels were also similar between CHF, IHF,
and NIHF patients (Figure 5E). Taken together, these findings
suggest that Treg cells from CHF patients were more prone to
apoptosis and that IL-2 and CD95/CD95L might be involved in
regulation of Treg-cell survival.
4. Treg cells accumulate neither in mediastinal lymph
nodes nor in failing hearts
One possible explanation for reduced Treg-cell number in CHF
patients is the reallocation of these cells to the lymph nodes or
disease-affected organs. We compared the proportion of
CD4
+CD25
+Foxp3
+ Treg cells to total CD4
+ T cells in the
mediastinal lymph nodes from CHF patients and non-CHF
controls. Mediastinal lymph node Treg cells from CHF patients
were significantly fewer than from non-CHF controls (Figure 6A/
6B). Total lymphocyte Foxp3 mRNA levels were also significantly
lower in CHF, IHF and NIHF patients than in non-CHF controls
(Figure 6C). To examine whether Treg cell accumulation in the
heart was different between CHF and non-CHF controls, Foxp3
RT-PCR was performed on biopsied cardiac samples. No
difference was found between failing hearts and hearts from
donors, although Foxp3 levels were low in all tested heart samples
(Figure 6C).
Discussion
As the final common pathway of many cardiovascular diseases,
CHF is a complex multi-step disorder and several mechanisms
participate in its pathogenesis. There is compelling evidence that
inflammation and autoimmune abnormalities play an important
role in the progression of heart failure [1,24,25]. Various
autoantibodies, which are directed against different cardiac
antigens, such as cardiac myosin, cardiac troponin I, cardiolipin,
beta1-adrenergic and M2 muscarinic receptors can be detected in
the serum of patients with NIHF or IHF [26–29]. These
autoantibodies can lead to cardiac injury, and they correlate with
the deterioration of cardiac function. Other autoimmune abnor-
malities include infiltration of T cells in endomyocardial biopsies
from patients with idiopathic dilated cardiomyopathy (DCM).
Additionally, the transfer of peripheral blood lymphocytes from
DCM patients to severe combined immunodeficiency (SCID) mice
leads to ventricular remodeling [30]. In animal models, lympho-
cytes from rats with IHF can recognize and kill normal neonatal
rat cardiac myocytes in vitro [31] and lead to autoimmune
myocarditis in vivo after adoptive transfer [32].
Treg cells play a key role in the control of inflammation and
autoimmune responses, and altered Treg cells predispose patients
for uncontrolled immune activation or autoimmunity [3]. CHF
patients were previously reported to have impaired Treg-cell
number and function, but the precise mechanism behind this
defect remains largely unknown [17]. In this study, we showed that
reduced Treg cell number and function in CHF patients might be
explained by impaired Treg-cell thymic output and increased
apoptosis of these cell populations.
Like other T cells, Treg cells develop in the thymus [33]. A small
fraction of Treg cells with a naı ¨ve CD45RA
+CD45RO
- surface
profile (nTreg) has recently been detected in the circulation.
However, this nTreg subset declines with age, as does thymic
Table 1. Clinical characteristics of study population.
CHF patients (n=52) NIHF patients (n=32) IHF patients (n=20)
Non-CHF controls
(n=43)
Age (year) 44613 40614 51684 2 612
Gender (Male/Female) 31/21 17/15 14/6 28/15
NYHA (II/III/IV) 25/21/6 12/16/4 13/5/2 —
LVEF (%) 35.3866.24 35.0666.41 35.966.09 —
LVEDD (cm) 6.1160.47 6.1660.5 6.0260.41 —
Hypertension (%) 37 16 70 0
NT-proBNP (pg/ml) 2955.5261971.55 2756.3361628.37 3176.862442.88 —
Medication (%)
ACEI/ARBs 90 91 90 0
Antisterone 42 47 35 0
Digitalis 31 28 35 0
b-Blocker 87 88 85 0
Diuretics 73 50 80 0
Data is presented as mean6SD, or number or percentage of patients or healthy controls (HCs). NIHF: non-ischemic heart failure; IHF: ischemic heart failure; NYHA, New
York Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; NT-ProBNP, N-terminal Pro B-type natriuretic peptide;
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0024272.t001
Mechanisms for Treg Defects in CHF Patients
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circulating Treg cells appear as a mature population with a
memory CD45RA
2CD45RO
+ phenotype; these mTreg cells are
stable throughout the life span, and the levels of mTreg cells
increase during aging [35,36]. nTreg cells could represent the de
novo generation of thymic lymphocytes, so the assessment of nTreg
Table 2. Absolute number of Treg,n T reg,m T reg and RTE-Treg in the study population.
CD4
+ T cells (10
6/L) Treg (10
6/L) nTreg (10
6/L) mTreg (10
6/L) RTE-Treg (10
6/L)
CHF patients (n=52) 341.956206.28 9.9265.78* 1.9261.24* 6.8464.30* 0.3160.24*
NIHF patients (n=32) 346.556205.81 10.5266.26* 2.0661.37* 7.3864.81* 0.3560.29*
IHF patients
(n=20)
334.606212.16 8.9664.92* 1.6960.97* 5.9763.27* 0.2560.13*
Non-CHF controls (n=43) 289.996155.36 13.9667.6 3.3362.07 9.5165.49 0.7060.43
Data is presented as mean6SD. Treg, regulatory T cells; nTreg,n a ı ¨ve Treg;m T reg, memory Treg; RTE-Treg, recent thymic emigrant Treg.* p,0.05 vs. non-CHF controls.
doi:10.1371/journal.pone.0024272.t002
Figure 1. Frequencies of the regulatory T (Treg)-cell subset in CHF patients and non-CHF controls. PBMCs of CHF patients (n=52, 32
NIHF and 20 IHF) and non-CHF controls (n=43) were included, and a 6-color flow cytometric analysis using mAbs specific for CD4, CD25, CD45RA,
CD45RO, CD31 and Foxp3 was performed. a. Representative FACS images from a non-CHF control. Dot plots show CD45RA and CD45RO expression
on gated CD4
+ T cells. Naı ¨ve and memory CD4
+ T cells were defined as CD45RA
+CD45RO
2 (R1) and CD45RA
2CD45RO
+ (R2), respectively. b. A small
subpopulation of memory Treg (mTreg) (upper panel) and naı ¨ve Treg (nTreg) (lower panel) cells expressing both CD25 and Foxp3 was detectable. c.
Histograms show the expression of CD31 on nTreg cells. Recent thymic export-Treg (RTE-Treg) cells were identified as CD4
+CD25
+Foxp3
+CD45RA
+C-
D45RO
2CD31
+ cells. d. Frequencies of total Treg,n T reg, and mTreg cells in different patient populations were determined as percentages of total CD4
+
T cells. e. The ratio of nTreg to mTreg cells in different subject populations. f. RTE-Treg cell frequency in different subject populations was presented as a
percentage of total Treg cells. *p,0.05 vs. non-CHF controls.
doi:10.1371/journal.pone.0024272.g001
Mechanisms for Treg Defects in CHF Patients
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we provided evidence that, in addition to decreased percentages of
nTreg and mTreg cells, a shift from nTreg cells toward mTreg cells
was evidenced by a reduced nTreg/mTreg cell ratio in CHF
patients. This result indicated the possibility that impaired thymic
export contributes to Treg cell defects in this patient population.
However, nTreg cells can proliferate after thymic output while
retaining their naı ¨ve phenotype [37]. CD31 has been used as a
direct marker of thymic output and enabled the discrimination of
recent thymic emigrant (RTE) Treg cells from peripherally
expanded nTreg cells [38]. Thus, the assessment of nTreg cells
co-expressing CD31 (RTE-Treg) is now used to evaluate the
thymic output of Treg cells. The significant reduction of peripheral
RTE-Treg cell content in CHF patients, when compared to the
non-CHF controls, suggests a reduction of thymic Treg-cell output
during the development of heart failure. An alternative approach
to determine impaired Treg-cell thymic output in CHF patients
was to assess intracellular concentration of TRECs in purified Treg
cells. TRECs are generated during the process of T-cell receptor
rearrangement in T-cell differentiation and do not duplicate
during mitosis. TRECs are diluted out during homeostatic or
antigen-driven T-cell proliferation in the periphery [18]. There-
fore, TRECs are enriched in the newly synthesized and exported
T-cell pool. nTreg cells, especially RTE-Treg cells, have higher
frequencies of TRECs as compared with mTreg cells [38]. TREC
content reduction in total Treg cells from CHF patients further
supported our hypothesis that the Treg-cell output in the thymus
of a CHF patient is functionally altered. Hass et al. recently
reported that Treg cells from patients with and without multiple
sclerosis showed different activities in suppressing T-effector cells.
However, such differences disappeared after depleting the RTE-
Treg cells, indicating a crucial role of RTE-Treg cells in the
functional properties of the entire Treg population [38]. Thus,
impaired thymus export of Treg cells could be associated not only
with the number but also with the functional defect of Treg cells in
CHF patients. Over the course of multiple sclerosis, for example,
patients appear capable of amplifying mTreg-cell subpopulations to
compensate for impaired thymic production of Treg cells [39]. In
the case of CHF, in contrast, the homeostatic control of Treg cells
seems to be disturbed. Both nTreg and mTreg cells were reduced in
CHF patients (Figure 1D).
The homeostasis of Treg cells is maintained by a balance
between Treg-cell generation and depletion. Apoptosis-induced
alteration of Treg-cell levels has been associated with several
diseases. For example, intrathyroidal CD4
+CD25
+ Treg cells from
patients with autoimmune thyroid diseases were prone to
apoptosis, which led to a local Treg-cell reduction [40]. In
contrast, patients with metastatic epithelial cancer demonstrated a
significantly elevated proportion of peripheral Treg cells, and these
cells were protected from apoptosis [41]. Apoptosis not only
reduces the number of Treg cells, but also reduces their functions.
By using T-effector cell suppression assays, Treg-cell apoptosis was
closely associated with their capacity to inhibit T-effector cell
proliferation [42]. In patients with type 1 diabetes, an increase in
apoptosis was correlated with a decline in the suppressive potential
of Treg cells [43]. As suggested by these studies, high sensitivity to
IL-2 deprivation or FasL-induced apoptosis may contribute in part
to the defect of Treg cells in CHF patients. Treg cells from CHF
patients were more susceptible to apoptosis following IL-2
deprivation. Upon antigen activation, T cells induce the
expression of CD95, a member of the tumor necrosis factor
receptor/nerve growth factor receptor superfamily that induces
apoptosis by binding to CD95L and subsequently activating
Table 3. Correlation analysis between Treg or its subset
frequency and NT-proBNP in CHF patients.
NT-proBNP
Treg nTreg mTreg
Coefficients 20.589 20.557 20.446
p values ,0.01 ,0.01 ,0.01
NT-proBNP, N-terminal Pro B-type natriuretic peptide; Treg, regulatory T cells;
nTreg,n a ı ¨ve Treg;m T reg, memory Treg.
doi:10.1371/journal.pone.0024272.t003
Figure 2, Analysis of intracellular T-cell receptor excision circle
(TREC) levels in purified Treg cells from CHF patients and non-
CHF controls. a. CD4
+CD25
+CD127
low Treg cells from CHF patients
(n=25, 14 NIHF and 11 IHF) and non-CHF controls (n=15) were isolated
by magnetic selection (left), and the TREC levels were determined by
RT-PCR (right; *p,0.01) and compared to non-CHF controls. b. RTE-Treg
frequencies were plotted against TREC levels in purified Treg cells from
CHF patients and non-CHF controls (r=0.75, p,0.001).
doi:10.1371/journal.pone.0024272.g002
Figure 3. Correlation between CD4
+CD25
+ Foxp3
+ Treg cells and
CD4
+CD25
+CD127
lowTreg cells. Frequencies of CD4
+CD25
+Foxp3
+
Treg cells were plotted against CD4
+CD25
+CD127
lowTreg cells in 47 CHF
patients and 38 non-CHF controls (r=0.91, p,0.001).
doi:10.1371/journal.pone.0024272.g003
Mechanisms for Treg Defects in CHF Patients
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in CHF patients had higher CD95 expression levels and were
more sensitive to CD95/CD95L-mediated apoptosis than those in
non-CHF subjects. Indeed, we also detected concurrent increases
in serum soluble CD95L levels in CHF patients, consistent with
prior observations [45]. These findings strongly suggest that the
CD95/CD95L pathway is an important regulator of Treg-cell
apoptosis in CHF patients.
After release from the thymus, Treg cells circulate continuously
from blood to lymphoid tissues. In disease conditions, the
expression of chemokine receptors, such as CCR4 and CCR8,
on Treg cells allows their migration and recruitment to the site of
inflammation [46]. In several human diseases, Treg cells
preferentially accumulate at lymphoid tissues or sites of affected
organs [47,48]. Therefore, it is possible that decreases in
peripheral Treg cells in CHF patients are caused by Treg-cell
reallocation rather than an overall decrease. To investigate this
possibility, we compared the Treg-cell numbers in the mediastinal
lymph nodes or Foxp3 expression in cardiac biopsies between
CHF patients and non-CHF controls. The results revealed that
Treg-cell frequency in the mediastinal lymph nodes or Foxp3
expression in hearts of CHF patients was no higher than that of
the non-CHF controls. However, this possibility could not be
excluded due to the very small sample number. In addition to
generation in the thymus, Treg cells can also be converted from
activated effector or memory CD4
+CD25
2 T cells in the
periphery [49]. Peripherally converted Treg cells and thymus-
generated Treg cells demonstrate a similar phenotype and
suppressive functions. It is possible that such peripheral T-cell
phenotype conversion was altered in CHF patients. This
hypothesis merits further investigation.
TNF-a is central in the inflammatory cytokines response in
CHF and play a role in the pathogenesis and clinical progression
of the disease [50]. IL-10, an anti-inflammatory cytokine, may
offer protection against TNF-a and an improvement in cardiac
function in CHF has been associated with an increase in IL-10
[51] or a decrease in TNF-a/IL-10 ratio [52]. Our data indicated
that Treg frequency was negatively correlated with serum level of
TNF-a or the TNF-a/IL-10 ratio (Figure S1). In both our
previous study [17] and the present study, we observed that total
Treg number was significantly negatively correlated NT-proBNP
which is considered as the most sensitive index of cardiac
dysfunction in CHF patients. Based on these observations, we
may speculate that Treg cells provided protection for the failing
Figure 4. Spontaneous apoptosis of Treg cells from CHF patients and non-CHF controls. PBMCs of 47 CHF patients and 38 non-CHF
controls were stained with anti-CD4, anti-CD25, anti-CD127, annexin-V and 7-AAD and analyzed by flow cytometry. a. Representative FACS analyses
from one non-CHF control and one CHF patient are shown. A small subpopulation of CD25
+CD127
low/2 cells were gated and identified as Treg cells
(left panels). The staining of annexin-V and 7-AAD was further analyzed on gated Treg cells (middle), and apoptosis levels of the Treg cells are
calculated as percentage of annexin-V
+7-AAD
2 cells among 7-AAD
2 cells (right; *p,0.01 vs. non-CHF controls). b. CD4
+CD25
+CD127
low/2 Treg cells
from CHF patients (n=25, 14 NIHF and 11 IHF) and non-CHF controls (n=15) were isolated by magnetic selection (left), and the expression of both
the anti-apoptotic gene Bcl-2 (top panel) and the pro-apoptotic gene Bak (bottom panel) was measured. *p,0.05 vs. non-CHF controls.
doi:10.1371/journal.pone.0024272.g004
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cardiac function in CHF patients. However, the direct effect of
Treg cells on cardiac dysfunction still needs to be studied in animal
model.
IL-10 and TGF- b1 have been identified as the main effector
cytokines of Treg cells [53]. We investigated the hypothesis that
impaired Treg-cell function was associated with the decreased
expression of these two cytokines. Disappointedly, we failed to
observe a decrease in the expression of either IL-10 or TGF- b1i n
CHF patients (Figure S2).
To conclude, our study revealed that both impaired export from
the thymus and enhanced apoptosis can account for impaired
Treg-cell number and function in CHF patients, offering a
mechanistic explanation for the phenotypes and providing possible
novel targets for CHF therapy through Treg-cell manipulation.
Materials and Methods
1. Subjects
samples were collected from 52 CHF patients (31 men and 21
women, 44613 years old) and 43 non-CHF controls (28 men and
15 women, 42612 years old). Peripheral blood mononuclear cells
(PBMCs) were prepared by Ficoll density gradient centrifugation
(Sigma, USA). Plasma was obtained after centrifugation and stored
at 280uC. CHF diagnoses were based on clinical history, physical
examination, echocardiography, chest X-ray, electrocardiography
and levels of N-terminal pro-brain natriuretic peptide (NT-
proBNP), according to available guidelines pertaining to CHF.
Patients were classified as having non-ischemic heart failure
(NIHF) (n=32, 17 men and 15 women) if they had no history of
myocardial infarction and did not have significant coronary artery
stenosis upon coronary angiography. Patients were considered to
have ischemic heart failure (IHF) (n=20, 14 men and 6 women) if
the coronary angiography presented significant coronary artery
disease (.50% stenosis in more than one major epicardial
coronary artery) or the patients had a history of myocardial
infarction or previous revascularization. Patients were excluded (1)
if they were currently treated with anti-inflammatory drugs, such
as non-steroidal anti-inflammatory drugs and steroids, (2) if they
had collagen disease, thromboembolism, disseminated intravascu-
lar coagulation, advanced liver disease, renal failure, malignant
disease, other inflammatory disease (such as septicemia, pneumo-
nia), valvular heart disease, or atrial fibrillation, or (3) if they had
pacemakers. Patients with higher serum cholesterol than the target
values after risk stratification [54], who received statin therapy
within 3 months, were also excluded. Mediastinal lymph nodes
Figure 5. IL-2 deprivation and FasL-mediated Treg-cell apoptosis. PBMCs were stained with anti-CD4, anti-CD25, anti-CD127, and apoptosis
was induced as described in Methods. a. IL-2 deprivation-mediated Treg-cell apoptosis between CHF patients (n=47) and non-CHF controls (n=38).
b. CD95 expression on gated Treg cells from CHF patients (n=47) and non-CHF controls (n=38). c. CD95L induced a dose-dependent apoptosis of Treg
cells from CHF patients after incubation with CD95L for 12 h (upper panel; data are means from three separate experiments). Apoptosis of Treg cells
from CHF patients in the presence of 100 ng/ml CD95L was plotted against time (lower panel; data are means from three separate experiments).
d. FasL-induced apoptosis of Treg cells from CHF patients and non-CHF controls (100 ng/ml FasL for 12 hrs). e. ELISA determination of plasma soluble
FasL levels in 47 CHF patients and 38 non-CHF controls. *p,0.05 vs. non-CHF controls.
doi:10.1371/journal.pone.0024272.g005
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24272[55] and left ventricular biopsies were obtained from six CHF
patients (three patients with dilated cardiomyopathy who under-
went cardiac transplantation and three patients with coronary
heart disease who underwent the combined bypass surgery and left
ventricular aneurysm resection) and three controls (heart graft
donors without cardiomyopathy who died in car accidents).
2. Ethics statement
The investigation conforms to the principles outlined in the
Declaration of Helsinki. The trial was approved by the ethics
committee of Tongji Medical College of Huazhong University of
Science and Technology and patients and controls provided
written informed consent.
3. Naı ¨ve Treg (nTreg), memory Treg (mTreg) and recent
thymic emigrant-Treg (RTE-Treg) cells in the circulation
A 6-color flow cytometry analysis was performed to determine
levels of nTreg,m T reg and RTE-Treg in the circulation. PBMCs
were stained with surface antibodies for APC/Cy7 anti-human
CD4, PE anti-human CD25, FITC anti-human CD45RA, Percp/
Cy5.5 anti-human CD45RO and PE/Cy7 anti-human CD31
(Biolegend) for 30 min at 4uC. After surface staining, cells were
fixed, permeabilized, and stained with APC anti-human Foxp3,
according to the manufacturer’s instructions (eBioscience, USA).
Antibody isotype controls were performed to ensure antibody
specificity. Stained cells were analyzed by flow cytometry with
FACS Aria (BD Biosciences, USA).
4. Treg2cell isolation
A two-step selection using a CD4
+CD25
+CD127
dim/2 Regula-
tory T cell Isolation Kit (Miltenyi Biotec, Germany) was used to
isolate Treg cells according to the manufacturer’s instructions.
Briefly, non-CD4
+ and CD127
high cells were magnetically labeled
with a cocktail of biotin-conjugated antibodies and anti-biotin
microbeads and subsequently depleted by negative selection. Pre-
enriched CD4
+ T cells were then labeled with anti-CD25
microbeads, and CD4
+CD25
+CD127
dim/2 Treg cells were isolated
by positive selection. FACS was used to confirm the purity (.90%)
of the isolated Treg cells.
5. Quantification of T-cell receptor excision circles (TRECs)
The WizardH Genomic DNA Purification Kit (Promega, USA)
was used to extract genomic DNA (gDNA) from purified Treg cells.
Quantitative real-time PCR on an ABI Prism 7900 sequence
detection system (Applied Biosystems, USA) was used to determine
the number of TRECs. Primer pairs and probes were as follows:
TREC: F: 59-aacagcctttgggacactatcg-39,R :5 9-gctgaacttattg-
caactcgtgag-39, probe: 59-6FAM-ccacatccctttcaaccatgctgacacctc-
TAMAR-39;
RAG2: F: 59-gcaacatgggaaatggaactg-39,R :5 9-ggtgtcaaattcatcat-
caccatc-39,p r o b e :5 9-6FAM-cccctggatcttctgttgatgtttgactgtttgtga-
TRAMRA-39. Data were expressed as TRECs/10
6 cells.
6. Apoptosis assays
Freshly isolated PBMCs were first stained with surface
antibodies APC/Cy7 anti-human CD4, PE anti-human CD25,
Percp/Cy5.5 anti-human CD95 (Fas) (Biolegend, USA) and Alexa
FluorH 647 anti-human CD127 (eBioscience, USA). Cells with the
phenotype CD4
+CD25
+CD127
low were identified as Treg cells.
Apoptosis was measured using annexin V and 7-aminoactinomy-
cin D (7-AAD) co-staining (Bender MedSystems, USA). The
proportion of annexin V
+7-AAD
2 apoptotic cells in 7-AAD
2
viable Treg cells and the surface expression of CD95 on Treg cells
were analyzed using FACS Aria (BD Biosciences, USA).
For IL-2 deprivation-mediated apoptosis, cells were stimulated
with 2 mg/ml plate-bound anti-CD3 (eBioscience, USA) and anti-
human IL-2 monoclonal antibodies (Peprotech, 2 mg/ml) for 3
days. For Fas ligand (FasL)-induced apoptosis, cells were
stimulated with gradient concentrations of soluble recombinant
FasL (Peprotech, USA) in complete RPMI1640 containing IL-2
(100 IU/ml) for 12 hrs [56]. CD4
+CD25
+CD127
low/2 Treg cells
were also gated for annexin V
+7-AAD
– to determine apoptotic cell
populations. Cell death was presented as (Percent of IL-2
deprivation- or FasL-mediated apoptosis - percent of apoptosis
in the absence of anti-human IL-2 or FasL) / (100% - percent of
cells in the absence of anti-human IL-2 or FasL)6100.
7. Soluble CD95 ligand (sCD95L) ELISA detection
Human FasL/TNFSF6 Quantikine ELISA Kit (R&D Systems,
USA) was used to determine the plasma sCD95L levels. The
minimal detectable concentration was 2.66 pg/ml, and intra-assay
and inter-assay coefficients of variation were ,10%. All samples
were measured in duplicate.
8. Treg-cell detection in mediastinal lymph node
Mediastinal lymph nodes were minced and filtered through a
cell strainer to create a single cell suspension preparation.
Lymphocytes were isolated using Ficoll-Hypaque, stained with
specific antibodies for CD4, CD25 and Foxp3, and subjected to
FACS analysis. The number of Treg cells in the lymph nodes was
quantified by flow cytometry.
Figure 6. Treg cells in mediastinal lymph nodes and hearts. a.
Representative FACS dot plots showed the presence of
CD4
+CD25
+Foxp3
+ Treg cells in the mediastinal lymph nodes. b.
Percentages of CD4
+CD25
+Foxp3
+ Treg cells in the mediastinal lymph
nodes were determined in six CHF patients (three with idiopathic
cardiomyopathy and three with ischemic cardiomyopathy) and three
controls without cardiomyopathy. c. Comparison of Foxp3 expression in
the mediastinal lymph nodes and hearts of CHF and non-CHF controls.
*p,0.05 vs. non-CHF controls.
doi:10.1371/journal.pone.0024272.g006
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Total RNA was extracted using Trizol lysis buffer (Invitrogen,
USA), and cDNA was prepared using the Revertra AceH kit
(Toyobo, Japan). Expression of target genes (Bcl-2 and Bak in
purified Treg and Foxp3 cells) in heart tissues and lymphocytes
isolated from mediastinal lymph nodes was quantified using the
SYBR Green Master Mix (Takara, Japan) on an ABI Prism 7900
Sequence Detection system (Applied Biosystems, USA). Primer
pairs were as follows:
Bcl-2: F, 5-tacctgaaccggcacctg-3, R, 5-gccgtacagttccacaaagg-3;
Bak: F, 5-cctgccctctgcttctgag-3, R, 5-ctgctgatggcggtaaaaa-3;
Foxp3: F, 59-gaaacagcacattcccagagttc-39,R ,5 9-atggcccagcggat-
gag-39
GAPDH: F, 59-ccacatcgctcagacaccat-39,R ,5 9-ggcaacaatatc-
cactttaccagagt-39
For each sample, the mRNA expression level was normalized to
that of GAPDH. The mean of duplicate measurements was
normalized and expressed as a ratio of target mRNA copies to
GAPDH mRNA copies.
10. Quantification of transforming growth factor (TGF)-a
and interleukin (IL)-10 expression in Treg cells
PBMCs were cultured in RPMI1640 containing 10% FBS and
stimulated with PMA (50ng/ml; Sigma-Aldrich, USA), ionomycin
(1 mg/ml, Sigma-Aldrich, USA) and monensin (1 mM,
eBioscience, USA) for 4 h. Cells were stained with surface
antibodies for APC/Cy7 anti-human CD4, PE anti-human
CD25 (Biolegend, USA), Alexa FluorH 647 anti-human CD127
(ebioscience, USA) for 30 min at 4uC. After surface staining, cells
were fixed, permeabilized, and stained with PE-cy7 anti-human
TNF-a or PE-cy7 anti-human IL-10 (Biolegend, USA). Stained
cells were analyzed by flow cytometry with FACS Aria (BD
Biosciences, USA).
11. Tumor necrosis factor (TNF)-a and IL-10 ELISA
detection
Commercial ELISA Kits (Invitrogen, USA) were used to
determine the plasma TNF-a and IL-10 levels. The minimal
detectable concentrations were 0.5 pg/ml and 0.78 pg/ml for
TNF-a and IL-10 respectively. All samples were measured in
duplicate.
12. Statistical analysis
Values are expressed as means 6 standard deviation (SD) or
percentage in the text and figures. For variables with normal
distribution and homogeneity of variance, independent t-test or
one-way analysis of variance (ANOVA) was used to test differences
among two or more groups. For skewed variables, either non-
parametric Kruskal-Wallis H test or Mann-Whitney U test were
used for analyses. For the ranked data, Pearson’s chi-square test or
Fisher’s exact test were used for the comparison between multiple
groups. Spearman’s correlation analysis was performed to
determine correlation between the variables. In all cases, two-
tailed, p,0.05 was considered significant.
Supporting Information
Figure S1 Correlation analysis between Treg frequency
and plasma levels of cytokines in CHF patients (n=20).
(TIF)
Figure S2 Comparison of intracellular IL-10 and TGF-
b1 in CD4
+CD25
+CD127
low Treg between CHF patients
(n=10) and healthy controls (n=10).
(TIF)
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